VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COSTEM 2022 | The benefits of haploidentical versus matched sibling donor HSCT for patients with R/R ALL

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, summarizes the research surrounding haploidentical and matched sibling donor hematopoietic stem cell transplantation (HSCT), and compares their efficacy in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter